Geo-Spatial Insights on TB

1. Geo-Spatial Mapping and TB Surveillance

• Geographic mapping of TB cases in Anambra State, Nigeria, helped identify high-burden areas for targeted interventions.
• Urban and peri-urban regions, particularly those with high population density, are major TB hotspots.
• Geo-spatial mapping, using low-cost tools like Google Earth, can enhance TB surveillance and guide early, targeted interventions in resource-limited settings. See also: Yoseph Samodra

2. TB and Diabetes Mellitus (DM) Co-Infection

• Studies in Uganda, Thailand, and other regions highlight the high prevalence of DM in TB patients.
• DM increases the risk of TB, leading to poorer outcomes like higher mortality, treatment complications, and a higher incidence of cavities and lung lesions in TB patients.
• DM-TB co-infection is more common in older individuals and those living in semi-urban areas, with TB-DM patients showing an altered immune response and increased susceptibility to severe disease.

3. Risk Factors and Predictors for MDR-TB and TB-DM

• Geo-spatial analysis aids in identifying MDR-TB hotspots, enabling earlier detection and improved management.
• Key risk factors for MDR-TB include age, history of TB treatment, and HIV status. In TB-DM patients, poor glycemic control and insulin resistance exacerbate susceptibility to MDR-TB.
• Age ≥40 and smoking history are significant predictors for TB-DM co-infection, and HIV co-infection may have a protective effect against DM in certain populations.

4. Challenges and Strategies in TB-DM Management

• Bi-directional screening for TB and DM is being implemented in high-burden countries like India and China, but challenges remain in cost-effectiveness, diagnostic sensitivity, and decentralized care systems.
• Managing TB-DM requires careful attention to drug interactions, as TB treatments (e.g., rifampicin) can reduce the efficacy of hypoglycemic drugs, while metformin remains a viable option.
• Monitoring and tailored treatment plans are critical for optimizing outcomes in TB-DM patients.

5. Immune Disruption and Diagnostic Challenges in TB-DM Patients

• Chronic hyperglycemia in DM impairs both innate and adaptive immunity, making individuals more susceptible to TB and increasing the likelihood of drug resistance.
• Immune dysfunction in TB-DM patients includes altered T-cell responses, macrophage dysfunction, and weakened ability to clear the Mycobacterium tuberculosis bacteria.
• Diagnostic tools like TST and IGRA have reduced sensitivity in TB-DM patients due to immune suppression, making early detection and accurate diagnosis more challenging.

References:

1. Ugwu, C.I., Chukwulobelu, U., Igboekwu, C., Emodi, N., Anumba, J.U., Ugwu, S.C., Ezeobi, C.L., Ibeziako, V. and Nwakaogor, G.U., 2021. Geo-spatial mapping of tuberculosis burden in Anambra State, South-East Nigeria. Journal of Tuberculosis Research, 9(01), p.51.
2. Lin, H., Shin, S., Blaya, J.A., Zhang, Z., Cegielski, P., Contreras, C., Asencios, L., Bonilla, C., Bayona, J., Paciorek, C.J. and Cohen, T., 2011. Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiology & Infection, 139(11), pp.1784-1793.
3. Lin HH, Shin SS, Contreras C, Asencios L, Paciorek CJ, Cohen T. Use of spatial information to predict multidrug resistance in tuberculosis patients, Peru. Emerg Infect Dis. 2012 May;18(5):811-3.
4. Kibirige, D., Andia-Biraro, I., Olum, R., Adakun, S., Zawedde-Muyanja, S., Sekaggya-Wiltshire, C. and Kimuli, I., 2024. Tuberculosis and diabetes mellitus comorbidity in an adult Ugandan population. BMC Infectious Diseases, 24(1), p.242.
5. Kibirige, D., Andia-Biraro, I., Kyazze, A.P., Olum, R., Bongomin, F., Nakavuma, R.M., Ssekamatte, P., Emoru, R., Nalubega, G., Chamba, N. and Kilonzo, K., 2023. Burden and associated phenotypic characteristics of tuberculosis infection in adult Africans with diabetes: a systematic review. Scientific Reports, 13(1), p.19894.
6. Buasroung, P., Petnak, T., Liwtanakitpipat, P. and Kiertiburanakul, S., 2022. Prevalence of diabetes mellitus in patients with tuberculosis: a prospective cohort study. International Journal of Infectious Diseases, 116, pp.374-379.
7. Bezerra, A.L., Moreira, A.D.S.R., Isidoro-Gonçalves, L., Lara, C.F.D.S., Amorim, G., Silva, E.C., Kritski, A.L. and Carvalho, A.C.C., 2022. Clinical, laboratory, and radiographic aspects of patients with pulmonary tuberculosis and dysglycemia and tuberculosis treatment outcomes. Jornal Brasileiro de Pneumologia, 48(06), p.e20210505.
8. Zheng, C., Hu, M. and Gao, F., 2017. Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden. Global health action, 10(1), p.1264702.
9. Al-Bari MAA, Peake N, Eid N. Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges. World J Diabetes 2024; 15(5): 853-866.
10. Ye, Z., Li, L., Yang, L., Zhuang, L., Aspatwar, A., Wang, L. and Gong, W., 2024. Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective. In Exploration (p. 20230138).

TBC 053